05/11/2024 Event

Augustine Therapeutics is proud to participate in the Clinical Trials in Rare Diseases Europe 2024

18/10/2024 Event

Augustine Therapeutics is proud to be sponsoring and participating to the iPSC Modelling in Neuromuscular Disorders (iMND) conference from October 23-25 in Leuven.

10/09/2024 Event

Augustine Tx Sponsoring and Participating to the Annual Global CMT Research Convention on Sep 26-28 2024, Cambridge-MA

03/09/2024 Press Release

Augustine Therapeutics Announces Appointment of Carl Bjartmar as Chief Medical Officer

26/06/2024 Press

Augustine Therapeutics' Series A1 round featured in De Tijd - June 26th, 2024

26/06/2024 Funding Press Release

Augustine Therapeutics announces €17 million Series A1 financing round

06/06/2024 Event

Augustine Therapeutics will be participating in the 2024 Peripheral Nerve Society (PNS) Annual Meeting

06/05/2024 Event

Augustine Therapeutics will be participating in the 3rd ALS Drug Development Summit on May 21-23, 2024 in Boston, MA

12/04/2024 Event

Augustine Therapeutics will be participating in the 24th Bio-Equity Europe

27/02/2024 Funding Press Release

Augustine Therapeutics awarded with a US ALS Association grant to advance novel selective HDAC6 inhibitors

06/10/2023 Event

Augustine Therapeutics will be participating to the BIO-EUROPE conference in Munich, Germany on 6-8 November 2023

12/09/2023 Press Release

Augustine Therapeutics expands its Leadership Team and R&D Platform, Enters Regulatory Development

28/07/2023 Event

We are proud to sponsor the 2023 Global CMT Research Convention at Royal Sonesta, Boston held on 22nd and 23rd September.

05/06/2023 Event

Augustine Tx is participating at the 2023 PNS (Peripheral Nerve Society) Annual Meeting at the Bella Center, Copenhagen

30/05/2023 Event

Augustine is proud to sponsor and attend the 1st European Charcot-Marie-Tooth Specialists Conference

03/04/2023 Event

Augustine Tx Participating in the 23rd Bio€quity Europe in May

02/03/2023 Funding Press Release

CMT Research Foundation collaborates with Augustine Therapeutics on new therapy against Charcot-Marie-Tooth disease

16/12/2022 Event

Augustine Therapeutics is Participating at J.P. Morgan's 41st Annual Health Care Conference in San Francisco

19/10/2022 Event

Augustine Therapeutics’ leadership team will be attending and presenting at two major conferences in London, UK

14/10/2022 Press

A short documentary about how ground-breaking research from VIB / KU Leuven, the VIB Discovery Sciences Team, and VIB/ UZ Leuven

11/03/2021 Funding Press Release

Augustine Therapeutics awarded 1.2 million euro VLAIO research grant to develop new medicines for neuromuscular diseases

10/02/2023 Event

Augustine Therapeutics' leadership team will be attending 16th European Life Science CEO Forum in Zurich, Switzerland

04/10/2022 Event

Augustine Therapeutics will be participating to the BIO-EUROPE 2022 conference in Leipzig, Germany

05/09/2022 Event

Augustine Therapeutics is proud to announce as one of the Sponsors and Participants of the 2022 Global CMT Research Convention

18/08/2022 Press

Augustine Therapeutics: time to reverse nerve damage in patients undergoing chemotherapy or with Charcot-Marie-Tooth disease

10/05/2022 Press Release

Augustine Therapeutics appoints Gerhard Koenig as Chairman and forms Clinical Advisory Board

05/05/2022 Event

Augustine Therapeutics to present at the BIO€QUITY Europe 2022

19/03/2021 Press Release

Augustine Therapeutics strengthens Board of Directors and sets up Scientific Advisory Board

18/03/2021 Press Release

Augustine Therapeutics appoints Sylvain Celanire as CEO to accelerate development of innovative medicines for rare neuromuscular diseases